|
[1] European Association for the Study of the Liver(EASL),European Association for the Study of Diabetes(EASD),European Association for the Study of Obesity(EASO). EASL-EASDEASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.
|
|
[2] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. e1.
|
|
[3] BALLESTRI S,ZONA S,TARGHER G,et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J]. J Gastroenterol Hepatol,2016,31(5):936-944.
|
|
[4] WIELAND A,FRANK DN,HARNKE B,et al. Systematic review:Microbial dysbiosis and nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2015,42(9):1051-1063.
|
|
[5] COPPLE BL,LI T. Pharmacology of bile acid receptors:Evolution of bile acids from simple detergents to complex signaling molecules[J]. Pharmacol Res,2016,104:9-21.
|
|
[6] ADAMS LA,WANG Z,LIDDLE C,et al. Bile acids associate with specific gut microbiota,low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Liver Int,2020,40(6):1356-1365.
|
|
[7] SAYIN SI,WAHLSTRM A,FELIN J,et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid,a naturally occurring FXR antagonist[J]. Cell Metab,2013,17(2):225-235.
|
|
[8] OUT C,PATANKAR JV,DOKTOROVA M,et al. Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4[J]. J Hepatol,2015,63(3):697-704.
|
|
[9] JIA W,XIE G,JIA W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol,2018,15(2):111-128.
|
|
[10] FIORUCCI S,DISTRUTTI E. Bile acid-activated receptors,intestinal microbiota,and the treatment of metabolic disorders[J]. Trends Mol Med,2015,21(11):702-714.
|
|
[11] KURDI P,KAWANISHI K,MIZUTANI K,et al. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria[J]. J Bacteriol,2006,188(5):1979-1986.
|
|
[12] WATANABE M,FUKIYA S,YOKOTA A. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents[J]. J Lipid Res,2017,58(6):1143-1152.
|
|
[13] MERRITT ME,DONALDSON JR. Effect of bile salts on the DNA and membrane integrity of enteric bacteria[J]. J Med Microbiol,2009,58(Pt 12):1533-1541.
|
|
[14] GADALETA RM,van ERPECUM KJ,OLDENBURG B,et al.Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J].Gut,2011,60(4):463-472.
|
|
[15] NATIVIDAD JM,LAMAS B,PHAM HP,et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice[J]. Nat Commun,2018,9(1):2802.
|
|
[16] AMBALAM P,KONDEPUDI KK,NILSSON I,et al. Bile enhances cell surface hydrophobicity and biofilm formation of bifidobacteria[J]. Appl Biochem Biotechnol,2014,172(4):1970-1981.
|
|
[17] ZHENG X,HUANG F,ZHAO A,et al. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice[J]. BMC Biol,2017,15(1):120.
|
|
[18] de FARIA GHETTI F,OLIVEIRA DG,de OLIVEIRA JM,et al.Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis[J]. Eur J Nutr,2018,57(3):861-876.
|
|
[19] SHERRIFF JL,O’SULLIVAN TA,PROPERZI C,et al. Its potential role in nonalcoholic fatty liver disease,and the case for human and bacterial genes[J]. Adv Nutr,2016,7(1):5-13.
|
|
[20] SHEN F,ZHENG RD,SUN XQ,et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease[J]. Hepatobiliary Pancreat Dis Int,2017,16(4):375-381.
|
|
[21] ZHU L,BAKER SS,GILL C,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients:A connection between endogenous alcohol and NASH[J]. Hepatology,2013,57(2):601-609.
|
|
[22] CARBAJO-PESCADOR S,PORRAS D,GARCA-MEDIAVILLA MV,et al. Beneficial effects of exercise on gut microbiota functionality and barrier integrity,and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease[J]. Dis Model Mech,2019,12(5):dmm039206.
|
|
[23] STANISLAWSKI MA,LOZUPONE CA,WAGNER BD,et al. Gut microbiota in adolescents and the association with fatty liver:The EPOCH study[J]. Pediatr Res,2018,84(2):219-227.
|
|
[24] SCHUMACHER JD,GUO GL. Pharmacologic modulation of bile acid-FXR-FGF15/FGF19 pathway for the treatment of nonalcoholic steatohepatitis[J]. Handb Exp Pharmacol,2019,256:325-357.
|
|
[25] MOUZAKI M,WANG AY,BANDSMA R,et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease[J]. PLo S One,2016,11(5):e0151829.
|
|
[26] CAUSSY C,HSU C,SINGH S,et al. Serum bile acid patterns are associated with the presence of NAFLD in twins,and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD[J]. Aliment Pharmacol Ther,2019,49(2):183-193.
|
|
[27] XI Y,LI H. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease[J]. Biomed Pharmacother,2020,121:109609.
|
|
[28] FANG Q,LI H,SONG Q,et al. Serum fibroblast growth factor19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels[J]. Diabetes Care,2013,36(9):2810-2814.
|
|
[29] SHIHABUDEEN MS,ROY D,JAMES J,et al. Chenodeoxycholic acid,an endogenous FXR ligand alters adipokines and reverses insulin resistance[J]. Mol Cell Endocrinol,2015,414:19-28.
|
|
[30] JIAO N,BAKER SS,CHAPA-RODRIGUEZ A,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut,2018,67(10):1881-1891.
|
|
[31] ADAMS LA,WANG Z,LIDDLE C,et al. Bile acids associate with specific gut microbiota,low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Liver Int,2020,40(6):1356-1365.
|
|
[32] PURI P,DAITA K,JOYCE A,et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids[J]. Hepatology,2018,67(2):534-548.
|
|
[33] TAN X,LIU Y,LONG J,et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease[J]. Mol Nutr Food Res,2019,63(17):e1900257.
|
|
[34] CHEVRE R,TRIGUEROS-MOTOS L,CASTAO D,et al.Therapeutic modulation of the bile acid pool by Cyp8b1knockdown protects against nonalcoholic fatty liver disease in mice[J]. FASEB J,2018,32(7):3792-3802.
|
|
[35] JENA PK,SHENG L,NAGAR N,et al. Synbiotics bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models[J]. J Nutr Biochem,2018,57:246-254.
|
|
[36] PATHAK P,XIE C,NICHOLS RG,et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism[J].Hepatology,2018,68(4):1574-1588.
|
|
[37] NATIVIDAD JM,LAMAS B,PHAM HP,et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice[J]. Nat Commun,2018,9(1):2802.
|
|
[38] MOURIES J,BRESCIA P,SILVESTRI A,et al. Microbiotadriven gut vascular barrier disruption is a prerequisite for nonalcoholic steatohepatitis development[J]. J Hepatol,2019,71(6):1216-1228.
|
DownLoad: